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Abstract
Background: One of the challenges facing the tuberculosis (TB) control programmes in resource-
limited settings is lack of rapid techniques for detection of drug resistant TB, particularly multi drug
resistant tuberculosis (MDR TB). Results obtained with the conventional indirect susceptibility
testing methods come too late to influence a timely decision on patient management. More rapid
tests directly applied on sputum samples are needed. This study compared the sensitivity, specificity
and time to results of four direct drug susceptibility testing tests with the conventional indirect
testing for detection of resistance to rifampicin and isoniazid in M. tuberculosis. The four direct tests
included two in-house phenotypic assays – Nitrate Reductase Assay (NRA) and Microscopic
Observation Drug Susceptibility (MODS), and two commercially available tests – Genotype®
MTBDR and Genotype® MTBDRplus (Hain Life Sciences, Nehren, Germany).
Methods: A literature review and meta-analysis of study reports was performed. The Meta-Disc
software was used to analyse the reports and tests for sensitivity, specificity, and area under the
summary receiver operating characteristic (sROC) curves. Heterogeneity in accuracy estimates
was tested with the Spearman correlation coefficient and Chi-square.
Results: Eighteen direct DST reports were analysed: NRA – 4, MODS- 6, Genotype MTBDR® –
3 and Genotype® MTBDRplus – 5. The pooled sensitivity and specificity for detection of resistance
to rifampicin were 99% and 100% with NRA, 96% and 96% with MODS, 99% and 98% with
Genotype® MTBDR, and 99% and 99% with the new Genotype® MTBDRplus, respectively. For
isoniazid it was 94% and 100% for NRA, 92% and 96% for MODS, 71% and 100% for Genotype®
MTBDR, and 96% and 100% with the Genotype® MTBDRplus, respectively. The area under the
summary receiver operating characteristic (sROC) curves was in ranges of 0.98 to 1.00 for all the
four tests. Molecular tests were completed in 1 – 2 days and also the phenotypic assays were much
more rapid than conventional testing.
Conclusion: Direct testing of rifampicin and isoniazid resistance in M. tuberculosis was found to be
highly sensitive and specific, and allows prompt detection of MDR TB.
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Background
Tuberculosis (TB) continues to be a leading cause of mor-
bidity and mortality in developing countries [1]. Global
efforts for TB control are being challenged by the steady
increase in drug-resistant TB, particularly multidrug resist-
ant tuberculosis (MDR TB), defined as resistance to at
least rifampicin (RIF) and isoniazid (INH). The World
Health Organization (WHO) estimates that 500,000 new
cases of MDR TB occur globally every year and MDR TB
has been reported in 2.9% and 15.3% among the new and
previously treated cases, respectively [2].
MDR TB requires 18–24 months of treatment with expen-
sive second line drugs some of which are injectable agents.
The cure rate is much lower than for drug susceptible TB,
only around 60% [3]. Therefore, it is crucial that MDR TB
should be detected as soon as possible, and measures
implemented to effectively control its further spread.
Conventional methods for detection of MDR TB involve
primary culture of specimens and isolation of Mycobacte-
rium tuberculosis (MTB), followed by drug susceptibility
testing (DST). This process, referred to as indirect suscep-
tibility testing has a long turn around time (TAT) of
around 2 months. The TAT is longest in the TB high bur-
den low-income countries where primary isolation and
indirect DST are almost exclusively performed on solid
medium. Use of liquid systems such as the BACTEC MGIT
960 system (Becton Dickinson, Sparks, Maryland, USA)
has improved TAT to about 25–45 days, but liquid culture
systems are in most cases not available where the need is
greatest [4].
Even though liquid-based indirect susceptibility tests have
improved the TAT, they are still not rapid enough to allow
timely decisions on patient management in case of MDR
TB. More rapid TB susceptibility tests are needed, particu-
larly in TB high burden countries. Recently, the focus has
shifted to rapid direct tests in which decontaminated res-
piratory samples are directly inoculated in drug-free and
drug-containing medium or amplified for detection of
MDR TB. Some of the direct tests being studied with pros-
pects for applicability in developing countries include the
Nitrate Reductase Assay (NRA); Microscopic Observation
Drug Susceptibility (MODS) assay, and more recently
molecular assays such as the Genotype® MTBDR (Hain
Life sciences, Nehren, Germany), and its newer version –
the Genotype® MTBDRplus.
The NRA test, initially introduced as an indirect assay is
performed on solid medium as for the proportion
method, though liquid-based assays have recently been
studied [5-9]. The medium is supplemented with potas-
sium or sodium nitrate at a concentration of 1000 mg/L to
act as a growth indicator. Live M. tuberculosis organisms
possess the nitro-reductase enzyme and will reduce nitrate
to nitrite, which is then detected as a pink-purple colour
when a detection reagent (Griess reagent) is added to the
tube [5]. A colour change in a drug-containing tube indi-
cates resistance. The MODS assay is a low-technology liq-
uid culture system performed in OADC-supplemented
7H9 broth on an ordinary tissue culture plate [10]. A cock-
tail of antibiotics – polymyxin B, amphotericin B, Nalid-
ixic acid, trimethoprim and azlocillin (PANTA) is added
to prevent growth of contaminating bacteria and fungi.
Incorporation of isoniazid and rifampicin in the wells fol-
lowed by inoculation of processed samples in the drug-
free and drug containing wells allows direct detection of
MDR TB. When M. tuberculosis grows in the broth, charac-
teristic cord-like structures can be seen under an inverted
microscope, permitting early detection of resistance [10-
16]. The MODS assay has been studied on both smear
positive and smear negative sputum samples with good
results [11], which is not the case with any other tests. The
GenoType®MTBDR assay is a molecular test that detects
the common mutations in the rpoB  and  katG  genes
responsible for resistance to rifampicin and isoniazid,
respectively [17]. The test involves DNA extraction, multi-
plex polymerase chain reaction (PCR), solid phase reverse
hybridization and detection of the resistance mutations
[18-20]. The Genotype® MTBDRplus  assay detects addi-
tional mutations in the rpoB gene and also in the inhA
gene promoter region, giving a higher sensitivity in resist-
ance detection [18,21-24].
Published studies have evaluated the performance of
direct testing with the above mentioned tests. However,
the data is spread in many different journals, which makes
it difficult to fully understand the performance of direct
testing, thereby delaying decisions on adoption of this
approach for prompt detection of MDR TB. In this study,
available data from individual study reports on direct test-
ing with the NRA, MODS, Genotype® MTBDR and Geno-
type® MTBDRplus was pooled and analysed for sensitivity,
specificity and time to results of direct testing against con-
ventional indirect susceptibility testing in detection of
MDR TB. The results of this meta-analysis are intended to
guide TB control programmes in TB high burden countries
to select for further operational study, highly sensitive and
specific rapid tests to identify MDR TB.
Methods
Study design
A literature review and meta-analysis was conducted.
Search strategy
Original articles published in English up to end of January
2009 were searched with PubMed and Google. Each of the
four tests was searched by its name, and the name com-
bined with the words 'tuberculosis drug resistance testing',BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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'rifampicin resistant tuberculosis', 'isoniazid resistant
tuberculosis', 'multi drug resistant tuberculosis testing'.
New links displayed beside the abstracts were followed
and retrieved. Finally, the bibliographies of each article
were carefully reviewed and relevant articles also
retrieved. A search in other databases did not reveal any
additional articles previously missed on PubMed or
Google searches.
Inclusion and exclusion criteria
Only study reports that had evaluated direct DST for
detection of resistance to RIF and/or INH in M. tuberculosis
were included. At least 3 independent direct DST reports
were required to qualify a test for the pooled data analysis.
Additionally, the study report must have had extractable
data to fill the 4 cells of a 2 × 2 table for diagnostic tests
(true resistant – TR, false resistant – FR, false susceptible –
FS and true susceptible – TS). Lastly, studies were included
if the reference standard test in the report was an indirect
assay i.e. proportion method (PM) on Lowenstein-Jensen
(L-J) or 7H10 agar, BACTEC 460, BACTEC MGIT 960 or a
MIC (minimum inhibitory concentration) test. One gen-
otypic study used DNA sequencing as the reference test
but was also included. Indirect DST assay reports or study
reports that used the test for reasons other than DST were
excluded from further analysis, as were study reports with-
out extractable data for a 2 × 2 table.
Quality of study reports
In a meta-analysis of diagnostic accuracy studies, factors
such as study design, patient selection criteria, reference
standard and blinding, may be related to overly optimistic
estimates of diagnostic accuracy [25]. We applied the
quality of diagnostic accuracy studies tool (QUADAS
tool) [26] to assess the quality of the reports included in
this analysis. The QUADAS tool has 14 items that assess
study design-related issues, and the internal and external
validity of the results of the study [26]. Each item may be
scored 'yes' if reported; 'no' if not reported; or 'unclear' if
the information in the article is inadequate to make an
accurate judgement.
Data extraction
Data from study reports was extracted twice. Data items
included author(s); year of publication; reference stand-
ard test; country where the study was conducted; sample
size; specimen type; values of true resistance (TR), false
resistance (FR), false susceptible (FS) and true susceptible
(TS); and the QUADAS items. The time to results (TTR) in
days from setting the test to obtaining results for 100% of
the samples in each study report was recorded. The aver-
age time for each test type was then calculated.
Data analysis
Accuracy estimates
Sensitivity, specificity, forest plots and summary receiver
operating characteristic (sROC) curves were analysed with
the Meta-Disc software, based on the fixed model effect
[27]. Sensitivity was defined as the proportion of drug
resistant TB strains correctly identified by the new test
(true resistant rate – TRR). Specificity was defined as the
proportion of susceptible isolates correctly identified by
the new test (true susceptible rate – TSR).
Statistical testing for heterogeneity in accuracy estimates
Threshold/cut off effect as a possible cause of variations in
sensitivity and specificity among the reviewed reports was
tested with the Spearman correlation coefficient between
the logit of sensitivity and logit of 1-specificity. Variation
due to factors other than threshold/cut off effect was
tested by visual inspection of the forest plots for (i) degree
of deviation of sensitivity and specificity of each study
from the vertical line corresponding with the pooled esti-
mates, (ii) Chi-square p-values and (iii) inconsistence
index.
Time to results
The average time to results was computed in MS office
excel 2007.
Results
Sixty-four reports were initially reviewed. Nineteen of
these had studied direct DST for detection of resistance to
rifampicin and/or isoniazid in M. tuberculosis. Eighteen of
the 19 reports fulfilled the inclusion criteria for the meta-
analysis. The study reports reviewed and meta-analysed or
excluded, plus reasons for the exclusion are shown in
table 1. The description of the 18 meta-analysed reports is
given in table 2.
Quality of study reports (QUADAS analysis results)
Thirteen (72%) of the 18 study reports had reported the
spectrum of patients or samples to be representative of
those to benefit from routine use of the test (QUADAS
item 1). Eight (44%) of the 18 study reports clearly
described the patient or sample selection criteria (QUA-
DAS item 2). Quality items 3 to 9 that relate to internal
validity of the assay results were reported in 67–100% of
the studies. Lastly, seven of the 18 studies reported on
blinding to the results of the reference test (items 10)
while five reported on blinding to the new tests results
(item 11). Un-interpretable results were reported in 13
(78%) of the 18 studies (item 13).
Sensitivity and specificity
Rifampicin
The pooled sensitivity and specificity for detection of
resistance to rifampicin was 99% and 100% with NRA,BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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96% and 96% with MODS, 99% and 98% with Genotype®
MTBDR, and 99% and 99% with the new Genotype® MTB-
DRplus, respectively. See forest plots figures 1 and 2.
Isoniazid
The pooled sensitivity and specificity for detection of
resistance to isoniazid was 94% and 100% for NRA, 92%
and 96% for MODS, 71% and 100% for Genotype®
MTBDR, and 96% and 100% with the Genotype® MTBDR-
plus, respectively. See forest plots figures 3 and 4.
Area under the sROC curve
The sROC curves are shown in figures 5 and 6 for
rifampicin and isoniazid, respectively. The area under the
sROC curves was 0.98 to 1.00 for each of the four tests for
both rifampicin and isoniazid, and the Cochrane (Q*)
index ranged from 0.95 to 0.99.
Heterogeneity in sensitivity and specificity among study 
reports
Table 3 presents for each test the Spearman correlation
coefficient between the logit of sensitivity and logit of 1-
specificity. The degree of deviation of sensitivity and spe-
cificity estimates from the vertical line corresponding with
the pooled estimates, the Chi-square p-values and incon-
sistence index (1-squared) are shown in the forest plots
for each test, figures 1, 2, 3, 4.
Time to Results (TTR)
The average time to 100% of the results was 23 days
(range 18–28 days) for the NRA and 21 days (range 15–
29) for MODS. One of the Genotype® MTBDRplus studies
reported TTR (2 days).
Discussion
This study aimed at assessing the sensitivity, specificity,
and time to results of the NRA, MODS, Genotype® MTBDR
and Genotype® MTBDRplus  tests for direct detection of
resistance to rifampicin and isoniazid compared with con-
ventional indirect DST. The results are intended to guide
TB control programmes in RLS to select for further opera-
tional study highly sensitive and specific tests with shorter
time to results for detection of MDR TB.
Sensitivity and specificity of in-house phenotypic assays
Direct NRA performed with excellent pooled sensitivity
and specificity for both rifampicin and isoniazid (94% –
100%). These findings indicate improved performance of
the test when compared to results in a review by Martin A
et al where sensitivity and specificity of direct NRA studies
was 88% – 100% [28]. The MODS test with the highest
number of direct DST studies showed good pooled sensi-
tivity and specificity (86–100%) but performance of the
MODS was slightly lower compared to the NRA.
Sensitivity and specificity of the commercially available 
genotypic assays
Both the Genotype® MTBDR and Genotype® MTBDRplus
showed excellent pooled sensitivity and specificity for
detection of resistance to rifampicin (96–100%). For iso-
niazid, sensitivity of the Genotype® MTBDRplus was high
(96%; 95% CI 93–98%) but it was low with the Geno-
type® MTBDR test (71%; 95% CI 62–78%). The pooled
specificity was excellent for both assays i.e. 100%. The
Genotype® MTBDR test was designed to detect the most
common mutations for INH resistance in the katG gene,
and these account for 50–80% of INH resistance in M.
tuberculosis [17]. The newer Genotype® MTBDRplus detects
additional mutations in the katG gene and also in the inhA
promoter region for isoniazid resistance [18], leading to a
higher sensitivity. Ling et al also found pooled sensitivity
and specificity of 98% and 99%, respectively for
rifampicin but for isoniazid sensitivity was 84%, though
specificity was also 100% [29]. In their analysis, direct and
indirect testing with both the old Genotype® MTBDR and
The Genotype® MTBDRplus test was combined, and this
could explain the higher sensitivity for detection of resist-
ance to isoniazid in their study. In our study the pooled
sensitivity for isoniazid resistance detection of 96% with
the Genotype® MTBDRplus alone means that this test per-
Table 1: Study reports reviewed and meta-analysed or excluded
Excluded reports, and reason
Test Reviewed 
reports
Analysed 
reports
No data for 2 × 2 
table
Indirect DST Diagnostic study Review study *Other reasons
NRA 22 4 0 16 0 2 0
MODS 19 6 0 2 7 1 3
Genotype® 
MTBDR
13 3 1 7 0 1 1
Genotype® 
MTBDRplus
10 5 0 5 0 0 0
Total 64 18 1 30 7 4 4
*Other reasons: Three MODS studies were excluded as they were either disinfection, impact on clinical decision-making or operational issues 
studies. The one study under Genotype MTBDR was a hetero-resistance study.
Abbreviations: DST = Drug Susceptibility Testing; MODS = Microscopic Observation Drug Susceptibility; NRA = Nitrate Reductase Assay.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Table 2: Description of meta-analysed reports (n = 18)
Test Author, 
(Year)
Ref Reference 
test
Country Sample Size Rifampicin Isoniazid Time 
(Days)
TR FR FS TS TR FR FS TS
NRA Affolabi D 
(2008)
[6] L-J PM Benin 144 6 1 0 137 14 1 0 129 18
Affolabi D 
(2007)
[7] L-J PM Benin 177 7 0 1 169 00 00 28
Solis LA 
(2005)
[8] L-J PM Peru 192 113 0 1 78 101 0 7 84 28
Musa HR 
(2005)
[9] L-J PM Argentina 121 11 0 0 110 13 0 1 107 18
TOTAL 634 137 1 2 494 128 1 8 320
MODS Ejigu GS 
(2008)
[10] MGIT 960 Ethopia 58 19 0 1 38 32 2 1 23 15
Mello FCQ 
(2007)
[13] L-J PM Honduras 180 72 18 3 87 89 19 3 69 24
Shiferaw G 
(2007)
[14] Agar PM Ethopia 247/246 24 1 2 220 50 6 3 187 29
Moore DAJ 
(2006)
[11] L-J PM Peru 338/334 36 0 0 302 64 1 10 259 15
Moore DAJ 
(2004)
[15] MABA-MIC Peru 276 31 7 2 236 63 8 10 195 ND
Caviedes L 
(2000)
[16] MABA-MIC Peru 88 16 9 0 63 22 1 0 65 ND
TOTAL 1187/1182 198 35 8 946 320 37 27 798
Genotype®
MTBDR
Hillemann D 
(2007)
[ 1 8 ] L - J  P M G e r m a n y 7 1 3 0113 93 6053 0 N D
Somoskovi A 
(2006)
[19] BACT 460 USA 130 25 3 0 102 50 0 38 47 ND
Hillemann D 
(2006)
[ 2 0 ] L - J  P M G e r m a n y 4 2 1 5002 71 7002 5 N D
TOTAL 243 70 4 1 168 103 0 43 102
Genotype®
MTBDRplus
Causse M 
(2008)
[21] MGIT 960 Spain 18 9 0 0 9 8 0 0 10 ND
Lacoma A 
(2008)
[22] BACT 460 Spain 51 29 1 0 21 28 0 2 21 ND
Miotto P 
(2008)
[23] Sequencing Italy 173/172 20 0 0 153 117 0 0 55 ND
Barnard M 
(2008)
[24] MGIT 960 S. Afrrica 454/452 94 2 1 357 114 1 7 330 2
Hillemann D 
(2007)
[ 1 8 ] L - J  P M G e r m a n y 7 1 3 0113 93 7043 0 N D
TOTAL 767/764 182 4 2 579 304 1 13 446
Abbreviations: BACT 460 = Radiometric BACTEC 460, FS = false susceptible, FR – false resistant, L-J PM = Proportion method on Lowenstein-
Jensen medium, MGIT = Mycobacterium growth indicator tube, MODS = Microscopic Observation drug susceptibility assay; ND = No data in study 
report, NRA = Nitrate Reductase Assay, Ref = Bibliographic reference, Time = Duration in days from setting the test to obtaining 100% of the 
results in the specified study, TS = true susceptible, TR = true resistant. The MODS assay has been studied on both smear positive and smear 
negative sputum samples with good results, which is not the case with any other tests.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Forest plots of sensitivity and specificity – Rifampicin phenotypic assays: 1a) Nitrate reductase assay; 1b) Microscopic Observa- tion drug susceptibility Figure 1
Forest plots of sensitivity and specificity – Rifampicin phenotypic assays: 1a) Nitrate reductase assay; 1b) 
Microscopic Observation drug susceptibility.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Forest plots of sensitivity and specificity – Rifampicin Genotypic assays: 2a) Genotype® MTBDR; 2b) Genotype® MTBDRplus Figure 2
Forest plots of sensitivity and specificity – Rifampicin Genotypic assays: 2a) Genotype® MTBDR; 2b) Genotype® 
MTBDRplus.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Forest plots of sensitivity and specificity – Isoniazid phenotypic assays: 3a) Nitrate reductase assay; 3b) Microscopic Observa- tion drug susceptibility Figure 3
Forest plots of sensitivity and specificity – Isoniazid phenotypic assays: 3a) Nitrate reductase assay; 3b) Micro-
scopic Observation drug susceptibility.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Forest plots of sensitivity and specificity – Isoniazid Genotypic assays: 4a) Genotype® MTBDR; 4b) Genotype® MTBDRplus Figure 4
Forest plots of sensitivity and specificity – Isoniazid Genotypic assays: 4a) Genotype® MTBDR; 4b) Genotype® 
MTBDRplus.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Summary receiver operating characteristic (sROC) curves – rifampicin testing Figure 5
Summary receiver operating characteristic (sROC) curves – rifampicin testing.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Summary receiver operating characteristic (sROC) curves – isoniazid testing Figure 6
Summary receiver operating characteristic (sROC) curves – isoniazid testing.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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forms excellent as a direct assay for INH as well. This is an
advantage over the old Genotype® MTBDR test, and the
related test – the Line Probe Assay (INNO-LiPA Rif TB
Assay; Innogenetics, Ghent, Belgium), which detects
mutations in only the rpoB gene for rifampicin but not iso-
niazid resistance [23,24,30]
Area under the sROC curve
Estimating mean sensitivity and specificity alone without
looking at the area under the sROC curve may result into
underestimation of test accuracy [31]. The area under the
sROC, which is also an estimate of test accuracy was
almost one for each test (see figures 5 and 6), meaning
that the probability of the test to correctly rank a random
pair of resistant and susceptible TB would be 98–100%.
The Cochrane (Q*) index, i.e. the point at which the
sROC crosses the diagonal line from the left upper coordi-
nate to the right bottom coordinate was excellent for each
of the four tests (see figures 5 and 6). At the Q* point, sen-
sitivity is equal to specificity and the false positive rate is
at the minimum [31]. With the high sensitivities, specifi-
cities, area under the sROC and Q* index, the diagnostic
accuracy for the direct NRA, MODS, and Genotype® MTB-
DRplus assays is high.
Heterogeneity in accuracy estimates
Variations caused by threshold/cut off effect are detected
by a Spearman correlation coefficient between the logit of
sensitivity and logit of 1-specificity with a significant p-
value [27,32,33]. The Spearman correlation coefficient
was not significant in most of the tests (table 3) except for
the NRA and the Genotype® MTBDR assays for INH. To
test for causes of variations other than threshold, visual
inspection of the forest plots showed very minimal devia-
tion of individual study estimates of sensitivity and specif-
icity from the pooled value, except for the Genotype®
MTBDR for INH. Furthermore, the MODS and the two
genotypic assays showed significant p-values for the Chi-
square, and a high inconsistency index for INH (see forest
plots). This implies that heterogeneity in sensitivity and
specificity due to chance, study design/population, and
the way a study was conducted could have caused the var-
iations in the latter tests [34,35]. Since pooling sensitivity
and specificity is more reliable in the absence of a thresh-
old effect, the NRA and the Genotype® MTBDR assays
should be primarily judged based on their areas under
sROC, while the other tests can be reliably judged based
on their pooled values.
Time to results (TTR)
We presented data for TTR for 100% of the DST results to
permit comparison of rapidity between the different tests.
For the MODS and NRA tests, the average TTR was within
23 days compared with the 2 months required for conven-
tional indirect testing. Moreover, most results were ready
in 7–14 days for MODS (data not shown). Contamina-
tion and indeterminate results in phenotypic methods
may prolong the time to the final result but this was diffi-
cult to quantify in this study. For the genotypic assays, the
only study that indicated TTR reported 2 days, but the pro-
tocol of these genotypic assays allows DST results within
1–2 days [36]. The risk of amplicon contamination is a
problem in PCR-based tests. This could prolong the time
to results as repeat testing or new samples have to be ana-
lysed. From this study however, it was evident that direct
testing with any of the studied tests significantly shortens
the time to detection of MDR TB, and would permit
timely decision on patient management. This is supported
by a retrospective study of the impact of direct MODS
assay in a clinical setting where DST results in 82.8% of
the cases were available before those of any standard
method. In 41% of these cases, the rapid results should
have prompted a timely modification in patient manage-
ment [37].
Even though, the potential for contamination, resulting in
un-interpretable or indeterminate results in phenotypic
direct tests were to be considered, the time periods shown
in this study were for 100% of the results. Additionally,
traditional reservations about the direct versus indirect
testing pertain in part to the inability to control the inoc-
ulum of a direct test. For rifampicin and isoniazid – the
Table 3: Spearman correlation coefficient Logit (sensitivity) vs Logit (1- specificity)
Test Rifampicin Isoniazid
Spearman correlation coefficient p-value Spearman correlation coefficient p-value
Nitrate Reductase Assay 0.400 0.600 1.000 0.000
MODS 0.086 0.872 0.143 0.787
Genotype® MTBDR 0.500 0.667 1.000 0.000
Genotype® MTBDRplus -0.200 0.747 -0.100 0.873
MODS = Microscopic Observation Drug Susceptibility. Note: A strong positive Spearman correlation coefficient between the logit of sensitivity 
and logit of 1-specificity suggests threshold/cutoff effect [27]. Since pooling sensitivity and specificity is more reliable in the absence of a threshold 
effect the NRA and the Genotype® MTBDR assays should be primarily judged based on their areas under sROC, while the other tests can be 
reliably judged based on their pooled values.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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two important drugs defining MDR TB, it appears that
inoculum size in direct assays is not as critical as previ-
ously believed. Moreover if MDR TB is identified then fur-
ther DST, including second line drugs can be undertaken.
It should be understood that the markedly shortened time
to results with rapid direct testing is meaningless in set-
tings where lengthy turn around time (TAT) is due to
delays in sample delivery to the laboratory or delays in
reporting the laboratory results. With that aside, it appears
that the choice of which direct test to customize in a given
setting will likely depend on some other operational
issues such as technical ease, cost and bio safety that are
briefly discussed below:
Technical ease
The NRA and MODS are technically simple to perform
and do not require sophiscated equipment when com-
pared with the conventional proportion method on
Lowenstein-Jensen (L-J) medium. The relative complexity
of the PCR-based genotypic tests compared with the NRA
and MODS may be a limitation to their use in resource-
limited settings (RLS). Genotypic assays require well
trained manpower though this is not as critical as previ-
ously believed [38]. Also required are equipment such as
sonicators, thermocyclers, hybridization instruments, and
a suitable laboratory infrastructure with unidirectional
work flow to minimize contamination. These resources
are not readily available in RLS and this could be a reason
why none of the analysed genotypic studies was con-
ducted in a typical RLS as shown in table 2.
Cost per test
Due to insufficient data, planned cost analysis was not
performed in this study. One report indicated MODS to
cost $3 per sample while another report from S. Africa
suggested that direct Genotype® MTBDRplus assay would
be 50% cheaper than conventional testing [12,24]. Direct
testing with the MODS or the NRA is probably cheaper
than molecular tests but since the time to results is short-
est with genotypic assays a cost-effective analysis is war-
ranted.
Bio safety
Conventional indirect testing requires sophisticated bio
safety level 3 laboratories with negative pressure air flow
to safely manipulate grown cultures at the time of the
DST. Conversely, direct DST is less demanding and the bio
safety risk is similar to that for workers doing microscopy
[39]. Direct DST may safely be performed in a TB lab with
N-95 masks for personal protection and a biological safety
cabinet as well as a laboratory door with a locker to stop
airflow turbulence [12].
Quality of analysed reports
The quality of the analysed reports was good in some but
not all aspects according to QUADAS analysis [26]. Three-
quarters of the study reports indicated the patient spec-
trum from whom the studied samples were obtained
(quality item 1), which is essential for the applicability
and specificity of the results. However, few studies indi-
cated the selection/sampling techniques, and those which
did used mostly convenience or biased sampling, casting
uncertainty about overall representativity and applicabil-
ity of the results. Prospective consecutive sampling of
patients to whom the test will be used is recommended
for diagnostic accuracy studies seeking to recommend any
new test for routine use [40]. Among all the reports, two
demonstrated the recommended design and conduct of a
diagnostic study, and followed the standards for reporting
diagnostic accuracy studies (STARD) [11,24,41]. Quality
items 3–9 which relate to the internal validity of the
results were excellent across all the analysed reports. It was
unclear if blinding was done or not in most studies (items
10 and 11), but un-interpretable results (item 13), a key
issue in direct testing were reported in almost eighty per-
cent of the studies. Quality items 12 and 14 were excluded
from analysis because the studies did not have a patient
follow up component.
Combining high test performance and the operational
issues discussed above, direct NRA and MODS assays
appear to be competing tests for TB laboratories at safety
level 2 in RLS. However, it is possible that in most of such
settings, laboratories are familiar with the L-J solid
medium-based assays, where NRA would require only a
minor adjustment to be implemented in the routines.
Other tests that have recently appeared in the literature
and proposed for TB high burden RLS include the Alamar
blue, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide), and resazurin assays [42]. Most
of these studies were performed as indirect assays. For
MTT and the manual mycobacterium growth indicator
tube (MGIT; Becton Dickinson, Sparks, Maryland, we
came across only two direct studies under each test [43-
46]. These tests were excluded from the meta-analysis
because the very few study reports made it difficult to give
conclusive comments on the methods.
Conclusion
Direct testing with the NRA, MODS and Genotype® MTB-
DRplus for MDR TB is highly sensitive and specific, and
significantly more rapid than conventional indirect sus-
ceptibility testing. The choice of which test to adopt will
likely depend on technical ease and cost-effectiveness
studies in the local settings, but the NRA and MODS
appear to be promising tests for RLS.BMC Infectious Diseases 2009, 9:67 http://www.biomedcentral.com/1471-2334/9/67
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Study Limitations
Few direct DST reports were available for our analysis.
This could be a limitation to generalization of the findings
in this study. Second, since not all the reviewed studies
fulfilled the study quality items in the QUADAS tool, the
results in some of the analysed reports could have affected
the pooled estimates shown in this study. However, some
authors simply don't report according to standards for
reporting diagnostic accuracy studies (STARD) even when
the studies themselves were performed well.
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